Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)

Recruiting

• Conditions: Myeloproliferative Neoplasm

• Registration Number: NCT06715267
• Lead Sponsor: University Hospital, Brest

Brief Summary

The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-01
• Study First Submitted: 2024-08-20
• Status Verified: 2024-12
• Study First Submitted QC: 2024-12-03
• Last Update Submitted: 2024-12-03
• Study First Posted: 2024-12-04
• Last Update Posted: 2024-12-04
• Primary Completion: 2038-04-01
• Study Completion: 2038-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
• Signature of the consent form for participation in the FIMBANK project.
• Agreement to participate in the VYP study.
• Patient of legal age at the time of inclusion in VYP.
• Patient affiliated to a social security scheme

Exclusion Criteria

• Refusal to participate by patients of full age
• Patient under legal protection (guardianship, curatorship, etc.)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe the epidemiological characteristics of the study population	at enrollment	Description of MPN subtypes according to age
Describe the mutational landscape of these MPNs	at enrollment	Rate of mutations JAK2/CALR/MPL

Secondary Outcome Measures

Name	Time	Method
Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1	At 10 years	Incidence of thrombosis
Describe the classical MPN outcomes-2	At 10 years	Incidence of myelofibrosis
Describe the classical MPN outcomes-3	At 10 years	Incidence of MDS/AML

Trial Locations

Locations (1)

CHU de Brest; 🇫🇷 Brest, France